Emmes
Emmes, founded in 1977, is a global clinical research organization specializing in a variety of therapeutic areas and managing over 32,000 clinical trial sites in more than 90 countries.
Company History of Emmes
Emmes was founded in 1977 and has been providing clinical research expertise for over 45 years. The company's long-standing history signifies its deep-rooted experience in the industry. Over the years, Emmes has grown to operate globally with a presence in over 90 countries, underscoring its expansive reach and international influence in clinical research.
Emmes' Global Operations
Emmes operates in over 90 countries worldwide, positioning itself as a global leader in the clinical research industry. With an extensive network and international reach, the company manages over 32,000 clinical trial sites, ensuring comprehensive and diverse trial conduct across different regions. Emmes' broad operational scope enables robust clinical research solutions on a global scale.
Clinical Trials and Therapeutic Areas at Emmes
Emmes specializes in a wide array of therapeutic areas including Vaccines and Infectious Diseases, Ophthalmology, Neuroscience, Rare Disease, and Cell and Gene Therapy. The company conducts Phase I, II, III, and IV clinical trials, demonstrating its capability to handle comprehensive clinical research projects across various stages. Emmes integrates technology and AI into clinical trials, notably through the launch of Veridix AI.
Specialized Services Offered by Emmes
Emmes offers specialized services essential for clinical trials such as biostatistics, clinical data management, pharmacovigilance, and medical monitoring. Additionally, the company provides regulatory affairs support, adhering to ICH guidelines and regional regulatory requirements. These services facilitate the smooth conduct of trials and ensure compliance with regulatory standards across multiple countries.
Emmes' Acquisition and Technological Advancements
Emmes has strategically enhanced its vaccine research capabilities and expanded its presence in Latin America through the acquisition of VaxTRIALS. The launch of Veridix AI signifies Emmes' commitment to integrating technology and artificial intelligence into clinical trials, enabling more efficient and innovative approaches to clinical research.